Perception and Prevalence of Fungal Infections in Berlin - Brandenburg (IFI_ICU)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Web-based Structured Survey of Retrospective Data of Invasive Mycosis in Intensive Care Patients in Berlin - Brandenburg|
- Perception and prevalence of fungal infections [ Time Frame: 4 months ] [ Designated as safety issue: No ]Perception and prevalence of fungal infections in ICU patients differs from real prevalence and leads to insufficient attribution of importance to this special medical condition.
- Practice - Surrogate markers for diagnosis and therapy of fungal infection and retrospective analysis of cases of invasive mycosis in a peer-review setting. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Qualitative and quantitative estimation of surrogate markers for diagnosis and treatment of invasive mycosis
Number of bloodcultures per year Rate of bloodcultures positive for fungi ICD-10 diagnosis ICU length of stay for patients with invasive mycosis and/or fungal infection Hospital mortality for patients with invasive mycosis and/or fungal infection Number of patients treated by antimycotics per year Mean duration of antifungal treatment Defined daily doses of antimycotics given by hospital pharmacy
|Study Start Date:||July 2011|
|Study Completion Date:||July 2013|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Participating hospitals in the INABBRA alliance.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01393002
|Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitaetsmedizin Berlin|
|Berlin, Germany, 13353|
|Study Director:||Claudia Spies, Prof., MD||Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitaetsmedizin Berlin|